ADIL
Price
$0.34
Change
+$0.11 (+47.83%)
Updated
Jun 26, 12:53 PM (EDT)
Capitalization
3.88M
SYRE
Price
$16.00
Change
+$0.59 (+3.83%)
Updated
Jun 26, 01:41 PM (EDT)
Capitalization
948.76M
35 days until earnings call
Interact to see
Advertisement

ADIL vs SYRE

Header iconADIL vs SYRE Comparison
Open Charts ADIL vs SYREBanner chart's image
Adial Pharmaceuticals
Price$0.34
Change+$0.11 (+47.83%)
Volume$55.04K
Capitalization3.88M
Spyre Therapeutics
Price$16.00
Change+$0.59 (+3.83%)
Volume$200
Capitalization948.76M
ADIL vs SYRE Comparison Chart in %
Loading...
ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADIL vs. SYRE commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADIL is a Hold and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ADIL: $0.25 vs. SYRE: $15.72)
Brand notoriety: ADIL and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADIL: 885% vs. SYRE: 52%
Market capitalization -- ADIL: $3.88M vs. SYRE: $948.76M
ADIL [@Biotechnology] is valued at $3.88M. SYRE’s [@Biotechnology] market capitalization is $948.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADIL’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ADIL’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ADIL is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADIL’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • ADIL’s TA Score: 4 bullish, 6 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ADIL.

Price Growth

ADIL (@Biotechnology) experienced а +2.93% price change this week, while SYRE (@Biotechnology) price change was +4.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.78%. For the same industry, the average monthly price growth was +31.36%, and the average quarterly price growth was +15.04%.

Reported Earning Dates

ADIL is expected to report earnings on May 14, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($949M) has a higher market cap than ADIL($3.88M). SYRE YTD gains are higher at: -32.474 vs. ADIL (-75.644). ADIL has higher annual earnings (EBITDA): -8.71M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. ADIL (2.37M). SYRE has less debt than ADIL: SYRE (0) vs ADIL (194K). ADIL (0) and SYRE (0) have equivalent revenues.
ADILSYREADIL / SYRE
Capitalization3.88M949M0%
EBITDA-8.71M-214.36M4%
Gain YTD-75.644-32.474233%
P/E RatioN/A1.72-
Revenue00-
Total Cash2.37M565M0%
Total Debt194K0-
FUNDAMENTALS RATINGS
ADIL vs SYRE: Fundamental Ratings
ADIL
SYRE
OUTLOOK RATING
1..100
5155
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
9864
P/E GROWTH RATING
1..100
5782
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADIL's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (75). This means that ADIL’s stock grew somewhat faster than SYRE’s over the last 12 months.

ADIL's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that ADIL’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ADIL (99). This means that SYRE’s stock grew similarly to ADIL’s over the last 12 months.

SYRE's Price Growth Rating (64) in the Pharmaceuticals Major industry is somewhat better than the same rating for ADIL (98). This means that SYRE’s stock grew somewhat faster than ADIL’s over the last 12 months.

ADIL's P/E Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as SYRE (82). This means that ADIL’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADILSYRE
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ADIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CDNA19.110.23
+1.22%
CareDx
SPRC0.32N/A
+0.76%
SciSparc Ltd
FMS27.73-0.07
-0.25%
Fresenius Medical Care AG
AGYS114.84-0.33
-0.29%
Agilysys
FNWD27.56-0.59
-2.10%
Finward Bancorp

ADIL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADIL has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ADIL jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADIL
1D Price
Change %
ADIL100%
+7.28%
SYRE - ADIL
39%
Loosely correlated
+2.01%
VANI - ADIL
37%
Loosely correlated
+2.36%
VTVT - ADIL
29%
Poorly correlated
+3.04%
BPMUF - ADIL
28%
Poorly correlated
N/A
GDTC - ADIL
27%
Poorly correlated
+0.06%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+2.01%
CGON - SYRE
58%
Loosely correlated
+1.01%
BEAM - SYRE
57%
Loosely correlated
-2.27%
IMNM - SYRE
56%
Loosely correlated
-2.69%
IDYA - SYRE
53%
Loosely correlated
+1.06%
ACLX - SYRE
53%
Loosely correlated
+1.07%
More